– USA, MD – OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the appointment of Harry J. D’Andrea to the company’s board of directors, effective April 29, 2016. He will serve as a member of the board’s audit committee and will stand for reelection for a one-year term at the company’s annual meeting of stockholders, to be held June 22, 2016.
Mr. D’Andrea brings to OpGen more than three decades of business, finance and investing experience, including serving as chief financial officer of three publicly traded companies. He also has served as a director of a dozen technology and healthcare companies.
He is currently managing general partner of Valhalla Partners, a venture capital firm he helped found in 2002. From 1999 to 2002, Mr. D’Andrea was chief financial officer of Advanced Switching Communications, Inc., a Nasdaq-listed company that completed its IPO in 2000. From 1989 to 1999 he held senior financial positions with a number of privately held and public companies. He also was a member of the Nasdaq Listings Qualification Panel from 2004 through 2014.
His public company board experience includes Martek Biosciences Corporation, where he was chairman of the audit committee and served from 2006 to 2011. Martek was acquired by Royal DSM N.V. in 2011 for $1.1 billion in an all cash transaction. Mr. D’Andrea was a director of Informax, Inc. from 1999 to 2002, also serving on the audit committee. He is currently a director of four privately held companies.
“We are fortunate to welcome Harry D’Andrea to the OpGen board of directors,” said Evan Jones, the company’s chairman and chief executive officer. “His deep and extensive financial and public company experience will be invaluable to OpGen as we grow into a leading rapid molecular diagnostics and bioinformatics company.”
Mr. D’Andrea is a board member of the Private Equity CFO Association and of The Pennsylvania State University Liberal Arts Alumni Society. He received a B.A. in Foreign Service from The Pennsylvania State University and an MBA from Drexel University.
About OpGen
OpGen, Inc. is developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, helping clinicians improve patient outcomes by providing more rapid information about life-threatening infections and decreasing the spread of infections caused by multidrug-resistant microorganisms. OpGen offers a full portfolio of in vitro diagnostic products and clinical laboratory services that employ state-of-the-art molecular diagnostics and bioinformatics. Its QuickFISH products are a suite of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures. Clinical laboratory services utilize the Acuitas products, including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, and Acuitas Lighthouse™ bioinformatics platform designed to detect, type, track and trend antibiotic resistant organisms in real-time.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
